Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the ...

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 ...

In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically ...

Shares of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) were trading at $1.65, down $2.45, or 59%, after the company disclosed phase II results from the Bestow trial testing tegoprubart, which targets ...

Purespring co-author paper with real world evidence on epidemiological prevalence data of NPHS2 pathogenic variants across global populations London – 4 November 2025 – Purespring Therapeutics, a ...

XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic ...

During the meetings, Maze Therapeutics will present additional pharmacokinetic data from its Phase 1 clinical trial of MZE782, as well as preclinical research supporting inhibition of SLC6A19 to slow ...

Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in NovemberTonmya is the first new FDA-approved ...

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN; ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuri ...